With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Corning on Tuesday announced its results for the fourth quarter and full year of 2013.�Core earnings per share were 29 cents, an increase of 4 percent over last year�� fourth quarter and better than expected. GAAP earnings per share were 30 cents.�Core sales were $2 billion, a 2 percent decline from the comparable period last year.��013 was a very successful year for Corning,��Wendell P. Weeks, chairman, chief executive officer, and president, said in the earnings report. ��e achieved the company�� primary performance goal of restoring earnings growth. This was accomplished by regaining positive momentum in our LCD business and growing the earnings in our other segments. We also delivered on our commitment to enhance shareholder value by increasing the cash dividend and executing more than $1.5 billion in share repurchases. The company�� performance was recognized by a 41% improvement in the year�� share price, a result with which we are delighted.��/p>
Top Industrial Conglomerate Companies For 2015: Teekay Corporation(TK)
Teekay Corporation engages in the marine transportation of crude oil and gas in Bermuda and internationally. Its Shuttle Tanker and FSO segment operates shuttle tankers, and floating storage and off-take (FSO) units for offloading and transportation of cargo from oil field installations to onshore terminals; and provides floating storage services for oil field installations. The company?s FPSO segment provides floating production, processing, and storage services through floating production, storage, and offloading (FPSO) units. Its Liquefied Gas segment comprises liquefied natural gas (LNG) and liquefied petroleum gas carriers. The company?s Conventional Tanker segment operates conventional crude oil and product tankers that are employed on long-term fixed-rate time-charter contracts. As of December 31, 2010, its fleet consisted of 151 vessels, including 11 vessels under construction. The company serves energy and utility companies, oil traders, oil and LNG consumers, p etroleum product producers, government agencies, and various other entities that depend upon marine transportation. Teekay Corporation was founded in 1973 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Teekay (TK) have surged more than 15% this morning after the shipping company announced a new dividend policy after yesterday’s close. Deutsche Bank’s Amit Mehrotra think the news is good enough to be worthy of an upgrade for Teekay:
ReutersWe are upgrading our recommendation on shares of Teekay Corp. to Buy from Hold, and raising our 12-month price target to $90 from $68. The revision reflects the company’s bold new dividend strategy outlined after today’s market close and ahead of its analyst day tomorrow. The new plan includes an 80% increase in its annual dividend effective 1Q15 (to $2.25 at the midpoint vs. $1.265 today), and a policy aimed at linking future div increases to cash flow growth at its two MLP subsidiaries [Teekay LNG Partners (TGP) & Teekay Offshore Partners (TOO)]. The result should be 20%/year grow in Teekay’s dividend for the foreseeable future, which together with today’s increase, easily justify a $90+ share price in the relatively near-term.
Investors clearly like the news. Shares of Teekay have soared 15% to $67.40 at 10:56 a.m., while Teekay LNG Partners has tricked up 0.3% to $43.56 and Teekay Offshore Partners is off 1.3% at $33.48.
- [By Lisa Levin]
Teekay (NYSE: TK) shares rose 13.26% to reach a new 52-week high of $66.10 after the company adopted a new dividend policy and announced its plans to increase dividend by 75%-80%.
- [By Lisa Levin]
Teekay (NYSE: TK) surged 14.67% to $66.92. The volume of Teekay shares traded 1390% higher than normal. Teekay adopted a new dividend policy and announced its plans to increase dividend by 75%-80%.
Top Life Sciences Companies To Own For 2014: MRG Metals Ltd (MRQ)
MRG Metals Limited is engaged in mineral exploration and production in Western Australia. The Company�� projects include the Xanadu gold project, the Mulgul copper prospect, the Braemore Battery prospect-Leonora, Diorite-Leonora and the Bellchambers. The Xanadu project consists of 14 prospecting license applications cover a total area of 26.7 square kilometers. The Mulgul exploration license application covers 336 square kilometers and is located 200 kilometers north of Meekatharra. The Company is acquiring nine granted prospecting licenses covering an area of 14.8 square kilometers, located five kilometers north of Leonora in the North-eastern Goldfields of Western Australia. Diorite is located 25 kilometers north of Leonora. There are three granted prospecting licenses covering an area of 5.42 square kilometers of greenstone lithologies. Effective June 28, 2013, MRG Metals Ltd (MRG) acquired Sasak Resources Australia Pty Ltd. Advisors' Opinion:- [By Magic Diligence]
Neustar's Lines of Business1) Numbering Services: 53% of total revenue, grew 7% in most recent quarter (mrq). These consist of databases that allow number portability - allowing customers to keep the same phone number even when changing cellular carriers or moving to a new address in the same area. Neustar is currently the sole provider of these services to the number portability administration center, or NPAC. We'll come back to this important fact later.
- [By Chuck Carnevale]
In addition to rewarding their shareholders through dividend increases and capital appreciation, Aflac has also been using its prodigious cash flows to purchase shares and reduce share count. Fewer shares outstanding support their ability to grow earnings per share to the benefit of shareholders. Common shares outstanding have fallen from 531 million shares in fiscal 1998 to 466 million shares in their most recent quarter (MRQ).
Top Life Sciences Companies To Own For 2014: Quest Diagnostics Inc (DGX)
Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.
Clinical Testing
The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.
The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.
The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.
The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.
In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.
Healthcare Information Technology
The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.
Clinical Trials Testing
The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.
Life Insurer Services
The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.
Employer Services
The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.
Diagnostic Products
Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.
HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.
The Company competes with Laboratory Corporation of America Holdings, Inc.
Advisors' Opinion:- [By Eric Volkman]
Quest Diagnostics'� (NYSE: DGX ) �first-quarter results have been released. For the quarter, net revenues were just under $1.79 billion, a drop from the $1.91 billion in the same period the previous year. Attributable net profit also declined, to $136 million ($0.85 per diluted share) from Q1 2012's result of $159 million ($0.99).
- [By Peter Graham]
The Q3 2014 earnings report for molecular diagnostic company Myriad Genetics, Inc (NASDAQ: MYGN) is due out after the market closes on Tuesday and things could get ugly since unlike potential diagnostic stock peers such as Rosetta Genomics Ltd (NASDAQ: ROSG) and mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX), it�� the most shorted stock on the Nasdaq with short interest of 52.07%. Aside from the Myriad Genetics earnings report, it should be said that Rosetta Genomics Ltd last reported earnings on March 31st and those�earnings were for the full year 2013 while�Quest Diagnostics reported Q1 2014 earnings on April 24th that were a disappointment due to restructuring costs and harsh winter weather. However, Myriad Genetics has been the more interesting stock as Medicare reimbursement rate increases and the lost of a court bid to block competition while a patent-infringement case is pending have sent its shares all over the place.
- [By Bryan Murphy]
What do Quest Diagnostics Inc. (NYSE:DGX) and Affymetrix, Inc. (NASDAQ:AFFX) know that the rest of the healthcare industry doesn't seem to know yet? In simplest terms, AFFX and DGX seem to have come to grips with the reality that there's so much information out there in the diagnostic and treatment world that caregivers are actually stumbling over it. The end result is not only care that's not better than it was in the recent past, but perhaps less effective than it used to be simply because of information overload and/or a lack of understanding of what to do with all sorts of data.
- [By Charles Carlson]
If you are new to DRIP investing, treat yourself to a few DRIPs this holiday season. Trust me��t'll change your life.
American Water Works (AWK)��ielding 2.7% with a DRIP minimum of $100
Cincinnati Financial (CINF)��ielding 3.2% with a DRIP minimum of $25
CVS Caremark (CVS)��ielding 1.4% with a DRIP minimum of $100
Dominion Resources (D)��ielding 3.4% with a DRIP minimum of $40
Domino's Pizza (DPZ)��ielding 1.2% with a DRIP minimum of $65
Eaton (ETN)��ielding 2.3% with a DRIP minimum of $100
Flowserve (FLS)��ielding 0.8% with a DRIP minimum of $100
Kellogg (K)��ielding 3.0% with a DRIP minimum of $50
New Jersey Resources (NJR)��ielding 3.7% with a DRIP minimum of $100
Quest Diagnostics (DGX)��ielding 2.0% with a DRIP minimum of $100
Tim Hortons (THI)��ielding 1.7% with a DRIP minimum of $25
Subscribe to Dow Theory Forecasts here��/p>
Top Life Sciences Companies To Own For 2014: Potomac Electric Power Company(POM)
Pepco Holdings, Inc., through its subsidiaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. It distributes electricity to approximately 1.8 million customers in the mid-Atlantic region and delivers natural gas to approximately 123,000 customers in Delaware. In addition, the company involves in the retail supply of electricity and natural gas; provision of energy efficiency services to federal, state, and local government customers; and designs, constructs, and operates combined heat and power and central energy plants, as well as owns and operates two oil-fired generation facilities. Further, it offers high voltage electric construction and maintenance services, low voltage electric construction and maintenance services, and streetlight construction and asset management services to utilities, municipalities, and other customers in the Washington, District of Columbia. Additionally, the company holds investments in eight cross-border energy leases. Pepco Holdings, Inc. was founded in 1896 and is based in Washington, District of Columbia.
Advisors' Opinion:- [By Sean Williams]
Powering up
It's pretty rare for stocks in the electric utility sector to see a prolonged dip given that electricity is a necessity product, but that's what we've seen from Mid-Atlantic electric utility provider Pepco Holdings (NYSE: POM ) .
Top Life Sciences Companies To Own For 2014: Nuance Communications Inc.(NUAN)
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers dictation and transcription solutions and services, which automate the input and management of medical information; and speech recognition solutions for radiology, cardiology, pathology, and related specialties that help healthcare providers dictate, edit, and sign reports without manual transcription. The company also offers mobile and consumer solutions and services comprising an integrated suite of voice control and text-to-speech solutions, desktop and portable computer dictation applications, predictive text technologies, mobile messaging services, and emerging services, such as dictation, Web search, and voicemail-to-text for manufacturers and suppliers of mobile phones, automotive products, personal navigation devices, computers, and other consumer electronics. In addition, it provides customer service business intelligence and authentication solutions for enterprises in the telecommunications, financial services, travel, entertainment, and government sectors to support, understand, and communicate with their customers. Further, the company offers document imaging, print management, and PDF solutions to multifunction printer manufacturers, home offices, small businesses, and enterprise customers; software development toolkits for independent software vendors; and licenses its software to multifunction printer manufacturers. Nuance Communications, Inc. markets and sells its products through direct sales force; its e-commerce Web site; and a network of resellers, including system integrators, independent software vendors, value-added resellers, hardware vendors, telecommunications carriers, and distributors. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in November 2005. Nuance Communications, Inc. was founded in 1992 and is headquartered in Burlington, Massachusetts. Advisors' Opinion:
- [By Anna Prior]
Activist investor Carl C. Icahn on Wednesday disclosed he increased his stake in Nuance Communications Inc.(NUAN) by 6.5 million shares. Mr. Icahn now owns a total of 58.9 million shares in the company, or a stake of nearly 19%, according to a filing with the Securities and Exchange Commission.
- [By Selena Maranjian]
Tudor Investment reduced its stake in lots of companies, including Nuance Communications (NASDAQ: NUAN ) . Nuance, specializing in speech-recognition software, took a dive in April after posting disappointing earnings. The company is threatened by weak demand, shrinking margins, and intensifying competition, as well as a change in how it's compensated, with more focus on usage. The stock's low valuation, with a forward P/E near 13 comparing favorably with its five-year average P/E of 42, makes it look attractive, but some doubt how quickly Nuance can grow. Notable investor Carl Icahn sees potential in it, though, perhaps intrigued by its potential in the health-care field, helping doctors create or update electronic health records.
- [By Selena Maranjian]
Other companies didn't do as well last year, but could see their fortunes change in the coming years. Nuance Communications (NASDAQ: NUAN ) , a major developer of speech-recognition software, shed 19%, in part due to some disappointing earnings. Nuance is threatened by weak demand, shrinking margins, and intensifying competition. Carl Icahn has taken a big stake in the company, but some doubt the wisdom of that. With its seemingly low valuation, some see it as a buyout candidate, and bulls like its prospects in health care.
- [By Laura Brodbeck]
Next week investors will be waiting for several key earnings reports, �including�Hewlett-Packard Company (NYSE: HPQ), Tiffany & Co. (NYSE: TIF), Nuance Communications, Inc.(NASDAQ: NUAN) and TiVo Inc. (NASDAQ: TIVO).
Top Life Sciences Companies To Own For 2014: Aussie/New Zealand (AR)
Antero Resources Corporation operates as an oil and natural gas exploration and production company. The company focuses on the acquisition, development, and production of unconventional oil and liquids-rich natural gas properties primarily in West Virginia, Ohio, and Pennsylvania. It was formerly known as Antero Resources Appalachian Corporation and changed its name to Antero Resources Corporation in June 2013. The company was founded in 2002 and is based in Denver, Colorado with district offices in Mount Clare, West Virginia; and Marietta, Ohio.
Advisors' Opinion:- [By Robert Rapier]
In February,�Antero Resources�(NYSE: AR) filed an S-1 with the SEC for the initial public offering of an MLP comprised of its midstream assets.�The filing�indicated that Antero Resources Midstream LLC would be converted into a limited partnership named Antero Midstream Partners LP with a valuation of up to $500 million. Assets include a network of natural gas gathering pipelines and compressor stations that collects raw natural gas from Antero’s operations in the Marcellus and Utica shales. Also included: two independent water distribution systems used for well completions in the Marcellus and Utica shales.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Antero Resources (NYSE: AR) were down 3.64 percent to $60.92 after the company announced a 105% y/y gain in its Q1 preliminary gas production. - [By Robert Rapier]
Supply, meanwhile, is constrained by the fact that, even at the current elevated price, few gas projects outside of the bountiful Marcellus shale can compete with the returns available in crude oil. Our favorite Marcellus drillers are Cabot Oil & Gas (COG) and Antero Resources (AR).
Top Life Sciences Companies To Own For 2014: Dynegy Inc (DYN)
Dynegy Inc. (Dynegy), incorporated in 2007, is a holding company and conducts the business operations through its subsidiaries. Dynegy�� primary business is the production and sale of electric energy, capacity and ancillary services from the fleet of 16 operating power plants in six states totaling approximately 11,600 megawatts of generating capacity. The Company sells electric energy, capacity and ancillary services on a wholesale basis from its power generation facilities. Its customers include Regional Transmission Organization (RTOs) and Independent System Operators (ISOs), integrated utilities, municipalities, electric cooperatives, transmission and distribution utilities, industrial customers, power marketers, financial participants, such as banks and hedge funds, and other power generators. Dynegy operates in three segments: the Coal segment (Coal), the Gas Segment (Gas) and the Dynegy Northeast Segment (DNE). In September 2011, it acquired direct ownership of Dynegy Coal Holdco, LLC. In July 2012, the Company announced that it has filed a voluntary petition to reorganize under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York, Poughkeepsie Division. It emerged from bankruptcy, on October 1, 2012. In May 2013, the Company sold its Roseton power generation facility (Roseton) to a subsidiary of Castleton Commodities International LLC (CCI).
Coal segment
Dynegy�� Coal segment consists of four operating coal-fired power generation facilities and two operating natural gas-fired peaker facilities in Illinois with a total generating capacity of 3,132 megawatts. On November 17, 2011, it permanently retired the 176 megawatts Vermilion power generation facility. As of December 31, 2011, the facilities operated entirely within MISO. Its Coal segment is primarily a fleet of baseload coal facilities, located in Illinois. The MISO market includes all of Wisconsin and portions of Michigan, Kentucky, Indian! a, Illinois, Nebraska, Kansas, Missouri, Iowa, Minnesota, North Dakota, Montana and Manitoba, Canada. MISO is as an independent RTO.
Gas Segment
Dynegy�� Gas segment consists of seven operating natural gas-fired power generation facilities located in California (two), Nevada (one), Illinois (one), Pennsylvania (one), New York (one), and Maine (one), and one fuel-oil fired power generation facility located in California, totaling 6,771 megawatts of electric generating capacity. On November 7, 2011, it deconsolidated DH, which indirectly owns all of its assets in the Gas segment. The PJM market includes all or parts of Delaware, Illinois, Indiana, Kentucky, Maryland, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Virginia, West Virginia and the District of Columbia. The Company�� Kendall and Ontelaunee facilities located in Illinois and Pennsylvania operate in PJM with an aggregate net generating capacity of 1,780 megawatts.
DNE Segment
Dynegy�� DNE segment consists of the Roseton and Danskammer facilities located in Newburgh, New York, with a total capacity of 1,693 megawatts. Its total of 1,570 megawatts of generation capacity relates to leased units at the two facilities. The Company�� Roseton and Danskammer facility sites are adjacent and share common resources, such as fuel handling, a docking terminal, personnel and certain associated systems.
Advisors' Opinion:- [By Bram de Haas]
Dynegy Inc (DYN) emerged from bankruptcy last year. The share price didn't really go anywhere. In the meantime 2013 free cash flow guidance is being revised upward to $190 million - $215 million and a deal to take over capacity from Ameren Corp (AEE) is likely to be finalized in the 4th quarter. On the basis of current cash flow, the company is fairly valued. If the Ameren facilities are added in, the cash flow of the combined facilities is greatly undervalued.
- [By Justin Loiseau]
Beyond the numbers
Duke Energy Corp is undergoing a major renovation. After an initial "intent-to-sell" press release in February, Duke officially announced in August that it would sell its merchant generation business to Dynegy (NYSE: DYN ) for $2.8 billion. CEO Good made clear that Duke didn't see a place for the "volatile low returns" it's recently experienced.� - [By Justin Loiseau]
Regulatory resilience
Ameren (NYSE: AEE ) and Dynegy (NYSE: DYN ) aren't letting regulatory snafus get in the way of their plans. The two companies published a statement this week assuring investors that despite the Illinois Pollution Control Board's denial of a variance relief transfer, Dynegy still plans to acquire Ameren Energy Resources. - [By Jayson Derrick]
Dynegy (NYSE: DYN) announced that it has acquired power generation assets from Duke Energy (NYSE: DUK) and Energy Capital partners. In total, Dynegy acquired 12.5 megawatts of coal and gas generation, almost doubling its existing assets to nearly 26,000 megawatts. Dynegy expects the acquisitions will create synergy targets of more than $40 million per year, $200 million in collateral efficiencies translating to nearly $500 million in present value cash savings. The company expects its adjusted EBITDA accretion to be 125 percent, while its free cash flow accretion will be 220 percent in 2015. Shares gained 8.75 percent, closing at $32.32.
No comments:
Post a Comment